Cargando…
Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400-2408.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
American Society of Hematology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759732/ https://www.ncbi.nlm.nih.gov/pubmed/31515233 http://dx.doi.org/10.1182/bloodadvances.2019000881 |
Ejemplares similares
-
Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
Publicado: (2019) -
Park EJ, Prajuabjinda O, Soe ZY, et al. Exosomal regulation of lymphocyte homing to the gut. Blood Adv. 2019;3(1):1-11.
Publicado: (2019) -
Lai C, Ranpura V, Wu C, et al. Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab. Blood Adv. 2019;3(7):980-983.
Publicado: (2019) -
Professor US Mathur
por: Singh, Virendra
Publicado: (2012) -
Bødker JS, Brøndum RF, Schmitz A, et al. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood Adv. 2018;2(18):2400-2411.
Publicado: (2019)